A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

NCT05577416 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Glioma

Interventions

PROCEDURE: Biopsy
DRUG: Part A: Safusidenib Erbumine
PROCEDURE: Surgery (maximal resection)
DRUG: Part B: Safusidenib Erbumine

Sponsor

Melbourne Health

Collaborators

[object Object]
[object Object]